Rna Diagnostics Inc announced today a new study to investigate RDA as a predictor for chemotherapy efficacy in canine lymphoma [...]

While the primary focus of RNA Disruption Assay (RDA) continues to be breast cancer chemotherapy management, it is rapidly evolving [...]

Rna Diagnostics announces the study, Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy, recently published in Breast Cancer Research and [...]

RNA Diagnostics, a Sudbury-based medical diagnostic company, has successfully closed an additional round of angel investment with support of the [...]

Interactive cost benefit model shows use of RDA in the neoadjuvant setting cost effective for German payers. Breast cancer stakeholders [...]

Rna Diagnostics aims for $150M in revenues by 2019 If all goes according to plan, a Toronto-based medical diagnostics company [...]